WO2003025138A3 - Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer Download PDF

Info

Publication number
WO2003025138A3
WO2003025138A3 PCT/US2002/029560 US0229560W WO03025138A3 WO 2003025138 A3 WO2003025138 A3 WO 2003025138A3 US 0229560 W US0229560 W US 0229560W WO 03025138 A3 WO03025138 A3 WO 03025138A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
modulators
screening
Prior art date
Application number
PCT/US2002/029560
Other languages
French (fr)
Other versions
WO2003025138A2 (en
Inventor
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Original Assignee
Eos Biotechnology Inc
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biotechnology Inc, Daniel Afar, Natasha Aziz, Kurt C Gish, Peter A Hevezi, David H Mack, Keith E Wilson, Albert Zlotnik filed Critical Eos Biotechnology Inc
Priority to CA002459219A priority Critical patent/CA2459219A1/en
Priority to AU2002330039A priority patent/AU2002330039A1/en
Priority to JP2003529912A priority patent/JP2005518782A/en
Priority to EP02766297A priority patent/EP1434881A4/en
Publication of WO2003025138A2 publication Critical patent/WO2003025138A2/en
Publication of WO2003025138A3 publication Critical patent/WO2003025138A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
PCT/US2002/029560 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer WO2003025138A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002459219A CA2459219A1 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002330039A AU2002330039A1 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2003529912A JP2005518782A (en) 2001-09-17 2002-09-17 Cancer diagnosis method, cancer modulator screening composition and method
EP02766297A EP1434881A4 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US60/323,469 2001-09-17
US32388701P 2001-09-20 2001-09-20
US60/323,887 2001-09-20
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US35514502P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,145 2002-02-08
US60/355,257 2002-02-08
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12

Publications (2)

Publication Number Publication Date
WO2003025138A2 WO2003025138A2 (en) 2003-03-27
WO2003025138A3 true WO2003025138A3 (en) 2003-05-08

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029560 WO2003025138A2 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (en)
JP (1) JP2005518782A (en)
AU (1) AU2002330039A1 (en)
CA (1) CA2459219A1 (en)
WO (1) WO2003025138A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425249T1 (en) 2000-06-16 2009-03-15 Biogen Idec Inc RENAL REGULATORY ELEMENTS AND THEIR USE
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP4527394B2 (en) 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Molecules and methods for inhibiting KIM-1 disruption
AU2002330713A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60220621T2 (en) 2001-11-09 2008-03-06 Proteologics, Inc. Posh nucleic acid, polypeptides and related methods
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003222965A1 (en) * 2002-04-05 2003-10-27 University Court Of The University Of Edinburgh Schizophrenia associated genes
WO2004001060A2 (en) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
EP1578762A4 (en) * 2002-11-12 2006-08-02 Wyeth Corp A novel pth responsive gene
JP4689275B2 (en) 2002-12-30 2011-05-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド KIM-1 antagonists and uses for modulating the immune system
JP4462964B2 (en) * 2003-03-10 2010-05-12 第一三共株式会社 Antibodies targeting cancer-specific antigens
WO2004090097A2 (en) 2003-04-03 2004-10-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
EP1923401A3 (en) * 2003-04-14 2008-08-20 Novartis AG Gene expression associated with osteoblast differentiation
EP1623230A2 (en) * 2003-05-05 2006-02-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2005001049A2 (en) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
CA2555656C (en) 2004-02-27 2017-03-28 Institut Curie New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2005103291A1 (en) 2004-04-27 2005-11-03 Takeda Pharmaceutical Company Limited Novel ligand of g-protein-conjugated receptor protein and use thereof
EP1747467A1 (en) * 2004-05-11 2007-01-31 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6)
CN102973947A (en) 2004-06-01 2013-03-20 健泰科生物技术公司 Antibody-drug conjugates and methods
CN101044164A (en) 2004-07-20 2007-09-26 健泰科生物技术公司 Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR20070061524A (en) 2004-07-20 2007-06-13 제넨테크, 인크. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US8206705B2 (en) 2005-03-02 2012-06-26 Biogen Idec Ma Inc. KIM-1 antibodies for treatment of TH2-mediated conditions
AU2006238475B2 (en) * 2005-04-18 2012-09-27 Opsona Therapeutics Limited Toll-like receptor 14 (TLR14 ) and use thereof
US7799519B2 (en) * 2005-07-07 2010-09-21 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
EP1959728A4 (en) * 2005-11-29 2010-02-10 Nevada Cancer Inst Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
JP5209505B2 (en) 2006-02-10 2013-06-12 ジェネンテック， インコーポレイテッド Anti-FGF19 antibody and method of use thereof
EP2366716A3 (en) 2006-03-21 2011-11-16 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
EP2152903A2 (en) * 2007-04-26 2010-02-17 Ludwig Institute for Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
CN101765434B (en) 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 Composition of tumour-associated peptides and related anti-cancer vaccine
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
EP2198306A1 (en) 2007-09-06 2010-06-23 Case Western Reserve University Methods for diagnosing and treating cancers
RU2490277C2 (en) 2007-09-26 2013-08-20 Дженентек, Инк. Novel antibodies
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
KR101667062B1 (en) 2008-07-15 2016-10-17 제넨테크, 인크. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
BRPI0917130A2 (en) * 2008-08-25 2015-12-01 Centocor Ortho Biotech Inc biomarkers for anti-tnf treatment of ulcerative colitis and related disorders
CN102257138B (en) 2008-10-20 2013-06-19 大日本住友制药株式会社 Tumor antigen peptide and use thereof
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
BRPI1006270B1 (en) 2009-03-25 2022-08-16 Genentech, Inc ANTI-A5SS1 ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL COMPOSITION, IN VITRO OR EX VIVO METHOD TO DETECT A5SS1 PROTEIN, USE OF AN ANTIBODY AND KIT TO DETECT A5SS1 PROTEIN
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
JP5918540B2 (en) 2010-01-29 2016-05-18 中外製薬株式会社 Anti-DLL3 antibody
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
CN114246952A (en) 2010-06-08 2022-03-29 基因泰克公司 Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
EA026827B1 (en) 2011-10-14 2017-05-31 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
CN108530535B (en) 2012-02-15 2021-02-26 诺和诺德股份有限公司 Antibody binding to peptidoglycan-recognizing protein 1
LT2814844T (en) 2012-02-15 2017-10-25 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
CN104797270A (en) 2012-08-02 2015-07-22 基因泰克公司 Anti-ETBR antibodies and immunoconjugates
CN104837502B (en) 2012-10-12 2018-08-10 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906253T (en) 2012-10-12 2018-11-05 Medimmune Ltd Pyrrolobenzodiazepine - anti-psma antibody conjugates
CA2887897C (en) 2012-10-12 2020-02-18 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd25 antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6392763B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES2687439T3 (en) 2013-03-13 2018-10-25 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
PT2970473T (en) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR102354207B1 (en) 2013-12-16 2022-01-20 제넨테크, 인크. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
AU2014364927A1 (en) 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
SG10201913702WA (en) 2014-07-17 2020-03-30 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
KR20170101895A (en) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (en) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
HRP20221063T1 (en) 2017-04-18 2022-11-11 Medimmune Limited Pyrrolobenzodiazepine conjugates
CN110536703A (en) 2017-04-20 2019-12-03 Adc治疗有限公司 Use Anti-AXL antibodies-drug conjugate combination treatment
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
PL3668874T3 (en) 2017-08-18 2022-03-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
CN111936520A (en) 2018-04-02 2020-11-13 百时美施贵宝公司 anti-TREM-1 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7085666B2 (en) 2020-03-31 2022-06-16 中外製薬株式会社 PLL3 target multispecific antigen-binding molecule and its use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114113603B (en) * 2021-06-30 2023-11-17 四川大学华西医院 Application of CYTL1 as gastric cancer prognosis marker

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194158B1 (en) * 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6194158B1 (en) * 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6440676B1 (en) * 1998-11-12 2002-08-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1434881A4 *
SMYTH TEMPLETON ET AL.: "Cloning and characterization of human tumor cell", INSTERSTITIAL COLLAGENASE, vol. 50, no. 17, September 1990 (1990-09-01), pages 5431 - 5437, XP000652150 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003025138A2 (en) 2003-03-27
JP2005518782A (en) 2005-06-30
EP1434881A2 (en) 2004-07-07
EP1434881A4 (en) 2005-10-26
AU2002330039A1 (en) 2003-04-01
CA2459219A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1892306A3 (en) Methods and kits for investigating cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2002021996A3 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2459219

Country of ref document: CA

Ref document number: 2003529912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002766297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002766297

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002766297

Country of ref document: EP